Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bausch & Lomb Names Praveen Tyle, Ph.D., Senior Vice President - Research & Development and Chief Scientific Officer.


ROCHESTER, N.Y. -- Bausch & Lomb (NYSE NYSE

See: New York Stock Exchange
:BOL BOL Bolivia (ISO Country code)
BOL Books Online
BOL Bole (SIL code, Nigeria)
BOL Bill Of Lading
BOL Beginning Of Line
BOL Best Of Luck
BOL Buzz Out Loud
BOL Bruin Online
BOL Beginning Of Life
) today announced that Praveen Tyle, Ph.D., is the global eye health company's senior vice president - Research & Development and chief scientific officer.

"Dr. Tyle brings to Bausch & Lomb a record of success in moving products from the laboratory to the market," said Bausch & Lomb Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  Ronald L. Zarrella. "Perhaps equally important is his extensive experience in drug development, an area of key strategic focus for our Company. We're confident he'll provide strong scientific leadership as the Company significantly increases its commitment to R&D."

Dr. Tyle joins Bausch & Lomb from Biovail Corporation where he served since 2003 as group vice president - pharmaceutical sciences and manufacturing. Prior to that, he spent nearly four years at Pharmacia Corporation, where he most recently was vice president and global head - pharmaceutical sciences.

Dr. Tyle has approximately 20 years of drug development and commercialization experience. He began his professional career as a formulations research chemist in drug delivery research with American Cynamid Company (now Wyeth), moving on to executive leadership and scientific positions with Sandoz Pharmaceuticals (now Novartis), Agouron Pharmaceuticals (now Pfizer) and Aronex Pharmaceuticals (now Antigenics). In 1999, Dr. Tyle was named vice president - pharmaceutical sciences, U.S., Pharmacia & Upjohn (now Pfizer).

Dr. Tyle holds academic appointments as an adjunct professor of Pharmacy at the University of Rhode Island History
The University was first chartered as the state's agricultural school in 1888. The site of the school was originally the Oliver Watson Farm, and the original farmhouse still lies on the campus today.
 and at the University of Houston, Texas “Houston” redirects here. For other uses, see Houston (disambiguation).
Houston (pronounced /'hjuːstən/) is the largest city in the state of Texas and the
.

He is editor of seven books about drug development, holds several patents and is author of more than 120 technical and scientific papers and presentations.

He received a Ph.D. degree in Pharmaceutics and Pharmaceutical Chemistry from the Ohio State University Ohio State University, main campus at Columbus; land-grant and state supported; coeducational; chartered 1870, opened 1873 as Ohio Agricultural and Mechanical College, renamed 1878. There are also campuses at Lima, Mansfield, Marion, and Newark.  in 1984 and a bachelor of Pharmacy A Bachelor of Pharmacy (abbreviated BPharm) is an undergraduate academic degree in the field of pharmacy. The degree is a basic prerequisite, in many countries, for registration to practice as a pharmacist.  degree from the Institute of Technology, Banaras Hindu University The Institute of Technology or IT-BHU is the engineering school of Banaras Hindu University (BHU) in Varanasi. It is one of India's oldest and highest-ranked engineering colleges. Like the rest of BHU, it is a residential and co-educational institute. , India, in 1980.

He is a member of the Council of Healthcare Advisors, the advisory board of Oakland University Center for Biomedical Research, and is a scientific advisor to CB Health Ventures of Boston and Epimmune, Inc., of San Diego. He also serves on the boards of directors of Orient Europharma Co. Ltd., Taiwan, and Interpath Pharmaceuticals, Houston.

Dr. Tyle succeeds Gary M. Aron who announced in April his plans to retire from Bausch & Lomb after 10 years. Aron will continue with the Company through a period of transition.

Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Celebrating its 150th anniversary, the Company is headquartered in Rochester, New York This article is about the city of Rochester in Monroe County. For the town in Ulster County, see Rochester, Ulster County, New York.
Rochester, once known as The Flour City, and more recently as The Flower City or
. Bausch & Lomb's 2003 revenues were $2 billion; it employs approximately 11,500 people worldwide and its products are available in more than 100 countries. More information about the Company can be found on the Bausch & Lomb Web site at www.bausch.com. Copyright Bausch & Lomb.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 19, 2004
Words:492
Previous Article:The Barbara Bush Foundation Awards $42,000 Grant to Forest Lake Area Schools.
Next Article:Lake Shore Gold Corp.: First Phase Resource Expansion Drilling Completed New Zone Discovered Timmins Gold Project, Ontario.
Topics:



Related Articles
BAUSCH & LOMB ANNOUNCES EXECUTIVE REALIGNMENT FOLLOWING RESIGNATION OF RONALD L. ZARRELLA.
BAUSCH & LOMB NAMES WILLIAM M. CARPENTER EXECUTIVE VICE PRESIDENT AND GLOBAL BUSINESS MANAGER-EYEWEAR; JAY T. HOLMES PROMOTED TO EXECUTIVE VICE...
BAUSCH & LOMB ANNOUNCES GILL'S RETIREMENT; CARPENTER NAMED PRESIDENT AND CHIEF OPERATING OFFICER; WALTRIP TO SERVE AS INTERIM CHAIRMAN AND CHIEF...
Bausch & Lomb Completes Regional Leadership Structure.
Bausch & Lomb Announces Departure of Americas Region President Mark M. Sieczkarek; CEO Ronald L. Zarrella to Oversee Region Until Replacement is...
FDA Accepts for Review Bausch & Lomb's New Drug Application for Retisert Implant for Non-infectious Posterior Uveitis.
Bausch & Lomb To Hold Investor Update, Live Webcast Dec. 1.
Bausch & Lomb and PTC Therapeutics Announce Anti-Angiogenesis Collaboration in Ophthalmology.
Bausch & Lomb Licenses Novel Compounds From Cephalon for Ophthalmic Use.
Bausch & Lomb Licenses rPlasmin from Talecris Biotherapeutics for Ophthalmic Use.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles